News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Big Pharma Quartet Dumps $30 Million Behind Aileron Therapeutics' P53 Peptide Drug


11/18/2013 8:07:26 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Aileron Therapeutics Inc . has turned to insiders for $30 million in Series E financing and secured full rights to a cancer drug designed to take the brakes off the tumor-suppressor gene p53. Cancers develop as the tumor-suppressing p53 gene becomes inactivated through mutation or through proteins that suppress its activity. Aileron has discovered a drug that may reactivate p53 when it's being held down by MDM2 and MDMX proteins.

Help employers find you! Check out all the jobs and post your resume.

Read at Dow Jones
Read at Boston Business Journal
Read at Xconomy

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES